3SV-31255-66613
3 vaccinations
1 coded response
24 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 911 / CA
- Registered
- 2020-12-24
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-18
Dose 1 — Pfizer-BioNTech
-
2020-12-24
Registered in v-safe
- 2020-12-26
- 2021-01-01
-
2021-01-08
Dose 2 — Pfizer-BioNTech
- 2021-01-08
-
2021-01-09
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Headache, Muscle or body achesAdult check-in
- 2021-01-10
- 2021-01-11
- 2021-01-12
- 2021-01-13
- 2021-01-14
- 2021-01-15
- 2021-01-22
- 2021-01-29
- 2021-02-05
- 2021-02-13
-
2021-02-19
Survey response — day 42, dose 2MedDRA: Rhinorrhoea — Feeling: GoodFree text: Runny nose after my 16 month old had the sameMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-04-11
- 2021-07-09
-
2021-09-15
Dose 3 — Pfizer-BioNTech
- 2021-09-28
- 2021-09-29
- 2021-10-06
- 2021-10-13
- 2021-10-30
- 2021-12-15
- 2022-03-16
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-18 | Pfizer-BioNTech | |
| 2 | 2021-01-08 | Pfizer-BioNTech | |
| 3 | 2021-09-15 | Pfizer-BioNTech | No |
Free text
Release 4 — day 42, dose 2
Symptoms: Runny nose after my 16 month old had the same
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Rhinorrhoea | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release